-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2020, the biomedical industry has received a lot of attention.
2021 is the first year of the 14th Five-Year Plan.
Based on a new starting point, a series of policies have been issued from the state to the local level to support the development and growth of the biomedical industry.
The industry ushered in vigorous development
.
In this context, the upstream biopharmaceutical equipment has also received great attention from the market.
The industry expects that under the new situation, the disposable system will gradually replace the traditional stainless steel reactor equipment
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The biomedical industry is ushering in a booming development.
The biomedical industry is one of China’s strategic emerging industries.
With the support of a series of favorable policies and the overweight of capital and talents, China's biomedical industry is ushering in a period of vigorous development, and its development prospects are very broad
.
Data shows that the market size of China's biopharmaceutical industry has grown from 350 billion yuan in 2019 to 400 billion yuan in 2020, and the scale of China's biopharmaceutical industry is expected to accelerate in the future
.
According to the Frost & Sullivan report, it is estimated that by 2024, the scale of China's biopharmaceutical market will break the $100 billion mark
.
Disposable systems will gradually replace stainless steel equipment.
In the context of the rapid development of the biomedical industry, related equipment industries in the industry chain will also face opportunities and challenges
.
The industry believes that in the future, disposable systems will gradually replace stainless steel equipment and penetrate into research, clinical and commercial scale applications
.
"Compared with traditional large-scale stainless steel bioreactors, the disposable system is more flexible, has a short construction period, low
initial investment costs, and higher production capacity, which can accelerate the commercialization of biomedical companies .
" According to BioPlan estimates, the current clinical practice 85% of pre- and clinical manufacturing are disposable systems
.
The expansion of the disposable system will involve the adoption of ≥ 2,000 commercial production lines based on disposable bioreactors, including the use of multiple bioreactors or the entire production line to run in parallel for horizontal expansion, instead of using large stainless steel bioreactors and production lines for traditional Scale up
.
The author understands that at present, disposable systems have been applied to most of the biopharmaceutical processing fields involving animal cell cultures
.
For example, in the production process of pre-clinical and clinical samples, disposable filters, disposable agitators, disposable bioreactors and other equipment have appeared
.
However, in terms of downstream processing, formulation and filling, the industry believes that the use of disposable systems still needs to be deepened
.
As far as the domestic biomedical industry is concerned, with the vigorous development of the innovative drug industry in recent years, medical bio-CDMO companies have seized the opportunity to actively expand their production capacity and use disposable bioreactors more widely
.
However, many pharmaceutical companies are still using traditional large-scale stainless steel bioreactors, which are time-consuming and labor-intensive, occupy a large space, and need to be equipped with special cleaning and disinfection equipment, resulting in low production efficiency of the company and a certain cost.
Of waste
.
As the biopharmaceutical industry advances towards high quality, the industry predicts that the market size of disposable bioreactors will usher in rapid growth in the future
.
In this context, pharmaceutical machinery companies in this field, such as Chutian Technology and Dongfulong, have also attracted the attention of the market
.
Recently, Chutian Technology responded to the organization in a survey report that the company has deployed disposable bioreactors, disposable liquid preparation systems, ultrafiltration chromatography purification, stainless steel reactors and fillers
.
Among them, in the field of disposable consumables, the company has introduced relevant technical talents in the industry and established a holding company Chutian Siyoute, which is used for the development of disposable bioreactors, liquid dispensing bags, liquid storage bags and their membrane materials.
And production
.
2021 is the first year of the 14th Five-Year Plan.
Based on a new starting point, a series of policies have been issued from the state to the local level to support the development and growth of the biomedical industry.
The industry ushered in vigorous development
.
In this context, the upstream biopharmaceutical equipment has also received great attention from the market.
The industry expects that under the new situation, the disposable system will gradually replace the traditional stainless steel reactor equipment
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The biomedical industry is ushering in a booming development.
The biomedical industry is one of China’s strategic emerging industries.
With the support of a series of favorable policies and the overweight of capital and talents, China's biomedical industry is ushering in a period of vigorous development, and its development prospects are very broad
.
Data shows that the market size of China's biopharmaceutical industry has grown from 350 billion yuan in 2019 to 400 billion yuan in 2020, and the scale of China's biopharmaceutical industry is expected to accelerate in the future
.
According to the Frost & Sullivan report, it is estimated that by 2024, the scale of China's biopharmaceutical market will break the $100 billion mark
.
Disposable systems will gradually replace stainless steel equipment.
In the context of the rapid development of the biomedical industry, related equipment industries in the industry chain will also face opportunities and challenges
.
The industry believes that in the future, disposable systems will gradually replace stainless steel equipment and penetrate into research, clinical and commercial scale applications
.
"Compared with traditional large-scale stainless steel bioreactors, the disposable system is more flexible, has a short construction period, low
initial investment costs, and higher production capacity, which can accelerate the commercialization of biomedical companies .
" According to BioPlan estimates, the current clinical practice 85% of pre- and clinical manufacturing are disposable systems
.
The expansion of the disposable system will involve the adoption of ≥ 2,000 commercial production lines based on disposable bioreactors, including the use of multiple bioreactors or the entire production line to run in parallel for horizontal expansion, instead of using large stainless steel bioreactors and production lines for traditional Scale up
.
The author understands that at present, disposable systems have been applied to most of the biopharmaceutical processing fields involving animal cell cultures
.
For example, in the production process of pre-clinical and clinical samples, disposable filters, disposable agitators, disposable bioreactors and other equipment have appeared
.
However, in terms of downstream processing, formulation and filling, the industry believes that the use of disposable systems still needs to be deepened
.
As far as the domestic biomedical industry is concerned, with the vigorous development of the innovative drug industry in recent years, medical bio-CDMO companies have seized the opportunity to actively expand their production capacity and use disposable bioreactors more widely
.
However, many pharmaceutical companies are still using traditional large-scale stainless steel bioreactors, which are time-consuming and labor-intensive, occupy a large space, and need to be equipped with special cleaning and disinfection equipment, resulting in low production efficiency of the company and a certain cost.
Of waste
.
As the biopharmaceutical industry advances towards high quality, the industry predicts that the market size of disposable bioreactors will usher in rapid growth in the future
.
In this context, pharmaceutical machinery companies in this field, such as Chutian Technology and Dongfulong, have also attracted the attention of the market
.
Recently, Chutian Technology responded to the organization in a survey report that the company has deployed disposable bioreactors, disposable liquid preparation systems, ultrafiltration chromatography purification, stainless steel reactors and fillers
.
Among them, in the field of disposable consumables, the company has introduced relevant technical talents in the industry and established a holding company Chutian Siyoute, which is used for the development of disposable bioreactors, liquid dispensing bags, liquid storage bags and their membrane materials.
And production
.
